FI931109A - Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus - Google Patents

Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus Download PDF

Info

Publication number
FI931109A
FI931109A FI931109A FI931109A FI931109A FI 931109 A FI931109 A FI 931109A FI 931109 A FI931109 A FI 931109A FI 931109 A FI931109 A FI 931109A FI 931109 A FI931109 A FI 931109A
Authority
FI
Finland
Prior art keywords
epstein
ebv
barr virus
antibodies
nucleic acid
Prior art date
Application number
FI931109A
Other languages
English (en)
Other versions
FI114802B (fi
FI931109A0 (fi
Inventor
Jaap Michiel Middeldorp
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI931109A0 publication Critical patent/FI931109A0/fi
Publication of FI931109A publication Critical patent/FI931109A/fi
Application granted granted Critical
Publication of FI114802B publication Critical patent/FI114802B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
FI931109A 1992-03-13 1993-03-12 Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä FI114802B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92200721 1992-03-13
EP92200721 1992-03-13

Publications (3)

Publication Number Publication Date
FI931109A0 FI931109A0 (fi) 1993-03-12
FI931109A true FI931109A (fi) 1993-09-14
FI114802B FI114802B (fi) 2004-12-31

Family

ID=8210477

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931109A FI114802B (fi) 1992-03-13 1993-03-12 Epstein-Barr-virukseen liittyviä peptidejä ja nukleiinihapposekvenssejä

Country Status (13)

Country Link
US (1) US5424398A (fi)
EP (2) EP1225226B1 (fi)
JP (3) JP4135996B2 (fi)
KR (1) KR100291247B1 (fi)
AT (2) ATE222291T1 (fi)
AU (1) AU666920B2 (fi)
CA (1) CA2092680C (fi)
DE (2) DE69334191T2 (fi)
DK (2) DK1225226T3 (fi)
ES (2) ES2184735T3 (fi)
FI (1) FI114802B (fi)
PT (1) PT574048E (fi)
ZA (1) ZA931797B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726315B1 (en) * 1993-07-23 2001-10-17 Hans Prof. Dr. Wolf Epstein-Barr virus DNA sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests
DE69432043T2 (de) * 1993-09-14 2003-10-09 Biomerieux B.V., Boxtel Diagnostische Reagenzien zum Nachweis von Antikörper gegen EBV
US5834747A (en) 1994-11-04 1998-11-10 Pixel Instruments Universal credit card apparatus and method
DE19526384C2 (de) * 1995-07-19 1997-07-10 Biotest Ag Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, sowie diese enthaltende Testkits zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
US5813500A (en) * 1996-03-25 1998-09-29 Tenneco Automotive Inc. Anti-swish mechanism for a damper
FR2765688B1 (fr) 1997-07-04 1999-09-10 Pasteur Institut Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications
US7105496B2 (en) * 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
WO1999018126A1 (fr) * 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
DE69940770D1 (de) 1998-03-04 2009-06-04 Biomerieux Bv Vervielfältigung und nachweis von ebv barf1 zur diagnose von nasopharyngealen karzinom
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
JP4981229B2 (ja) * 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
WO2003033520A2 (en) * 2001-09-24 2003-04-24 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20050063947A1 (en) * 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US6886670B2 (en) * 2003-09-29 2005-05-03 Tenneco Automotive Operating Company Inc. Extra support land for valve disc
DE10307517A1 (de) * 2003-02-21 2004-09-02 Mikrogen Molekularbiologische Entwicklungs-Gmbh Von Kapsidantigenen des Epstein-Barr-Virus abgeleitete Peptide und ihre Verwendung
US6899207B2 (en) 2003-09-29 2005-05-31 Tenneco Automotive Operating Company Inc. Extra support area for valve disc
EP1781826A4 (en) * 2004-06-12 2009-04-29 Univ Oregon Health & Science COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ORTHOPOXVIRUS
US7278987B2 (en) * 2004-07-09 2007-10-09 Anthony Solazzo Ergonomic urological catheterization/irrigation tray
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP2314349B1 (en) 2005-12-01 2016-03-09 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-viral griffithsin compounds, compositions, and methods of use
EP2172210A1 (en) 2005-12-23 2010-04-07 Partnership&Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion
US7868228B2 (en) 2006-01-31 2011-01-11 Monsanto Technology Llc Phosphopantetheinyl transferases from bacteria
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
CA2737595C (en) 2008-10-14 2017-09-12 Monsanto Technology Llc Utilization of fatty acid desaturases from hemiselmis spp.
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2673297A2 (en) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EP2813849A1 (en) * 2013-06-10 2014-12-17 Charité-Universitätsmedizin Berlin (Charité) EBV-specific immune signature as diagnostic markers in Chronic Fatigue Syndrome (CFS)
AU2015204680B2 (en) 2014-01-09 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-viral cnidarins
WO2016130628A1 (en) 2015-02-10 2016-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Griffithsin mutants
WO2016130899A1 (en) 2015-02-13 2016-08-18 The Board Of Trustees Of The University Of Illinois Peptide inhibition of ccr3-mediated diseases or conditions
WO2016201503A1 (en) 2015-06-15 2016-12-22 Monash University Il-37 variants
WO2017070744A1 (en) 2015-10-30 2017-05-04 Monash University Methods and compositions for improving glucose metabolism
CN108490177B (zh) * 2018-02-08 2020-12-29 深圳市新产业生物医学工程股份有限公司 鼻咽癌抗体检测试剂、其制备方法及鼻咽癌检测试剂盒
EP4003393A1 (en) 2019-07-29 2022-06-01 The Board Of Trustees Of The University Of Illinois Composition and method for promoting wound healing
EP4077363A1 (en) 2019-12-20 2022-10-26 F. Hoffmann-La Roche AG Il-37 fusion proteins and uses thereof
US20240002445A1 (en) 2020-11-18 2024-01-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Tyrosyl-lock peptides
WO2023192802A1 (en) 2022-04-01 2023-10-05 The Board Of Trustees Of The University Of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291636A1 (en) * 1983-11-07 1988-11-23 The Wistar Institute Immune response to viruses induced by anti-idiotype antibodies
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
WO1991002091A1 (en) * 1989-08-10 1991-02-21 Northwestern University Method of identifying herpesviruses and oligonucleotides for use therein
EP0585216A1 (en) * 1989-11-24 1994-03-09 The Council Of The Queensland Institue Of Medical Research Im peptides
PH31669A (en) * 1989-12-20 1999-01-18 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma.
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ｅｂｎａ抗体の測定方法および抗ｅｂｎａ抗体測定キット

Also Published As

Publication number Publication date
PT574048E (pt) 2002-12-31
JP4106041B2 (ja) 2008-06-25
AU666920B2 (en) 1996-02-29
JP2004261183A (ja) 2004-09-24
ES2184735T3 (es) 2003-04-16
FI114802B (fi) 2004-12-31
CA2092680C (en) 2006-08-08
JP4365440B2 (ja) 2009-11-18
ATE380243T1 (de) 2007-12-15
ZA931797B (en) 1993-09-30
ES2298325T3 (es) 2008-05-16
DK0574048T3 (da) 2002-12-16
EP1225226A1 (en) 2002-07-24
DE69332197T2 (de) 2003-04-17
FI931109A0 (fi) 1993-03-12
ATE222291T1 (de) 2002-08-15
DK1225226T3 (da) 2008-04-14
JPH0690787A (ja) 1994-04-05
AU3515293A (en) 1993-09-16
JP2008261851A (ja) 2008-10-30
JP4135996B2 (ja) 2008-08-20
CA2092680A1 (en) 1993-09-14
KR930019829A (ko) 1993-10-19
KR100291247B1 (ko) 2001-06-01
DE69332197D1 (de) 2002-09-19
EP0574048A2 (en) 1993-12-15
EP1225226B1 (en) 2007-12-05
US5424398A (en) 1995-06-13
EP0574048B1 (en) 2002-08-14
DE69334191T2 (de) 2008-11-27
DE69334191D1 (de) 2008-01-17
EP0574048A3 (fi) 1994-03-02

Similar Documents

Publication Publication Date Title
FI931109A (fi) Peptider och nukleinsyrasekvenser, som haenfoer sig till epstein-barr-virus
DE69132332D1 (en) Hepatitis c-virus-epitope
PT102022A (pt) Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca
HU9303703D0 (en) Hepatitis c virus (hcv) polypeptides
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
EP0151079A3 (en) Vaccine against epstein-barr virus
AU571128B2 (en) Expression of immunologically reactive aids viral protein
CA2057052A1 (en) Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof
AU1814692A (en) Method for detecting bovine diarrhoea virus infection, nucleotide sequence encoding a protein induced by this virus infection and recombinant proteins and antigens relating thereto
DK326289A (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
DK498387A (da) Virus-dna-sekvens
CA2084521A1 (en) Hepatitis c virus antigen polypeptide, production method therefor, and antibody detection method
EP0754755A3 (de) Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, diese enthaltende Testkits und Verfahren zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
Bopp et al. Comparative studies on novel protein antigens of streptococci of the serological group B
FI910587A0 (fi) Syntetiska polypeptider och antikroppar, vilka haenfoer sig till epstein-barr-virusets nukleaera antigen.
Greenham et al. Application of potassium thiocyanate as a destaining agent for confirming the specificity of viral immunofluorescence
RU98119633A (ru) Способ получения полипептида, обладающего антигенной активностью вируса гепатита е. набор для определения антител к возбудителю гепатита е - вирусу гепатита е

Legal Events

Date Code Title Description
MA Patent expired